Skip to content

Feasibility and efficacy of the de-escalation therapy by Biapenem for postoperative bacterial pneumonia.

Feasibility and efficacy of the de-escalation therapy by Biapenem for postoperative bacterial pneumonia. - Feasibility and efficacy of the de-escalation therapy by Biapenem for postoperative bacterial pneumonia.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000017219
Enrollment
20
Registered
2015-04-22
Start date
2013-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative pneumonia after esophagectomy for esophageal cancer

Interventions

Intravenous administration of Biapenem 300mg every six hours for the patient of postoperative pneumonia after esophagectomy

Sponsors

Department of Gastrointestinal Surgery, The University of Tokyo Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Canditates for esophagectomy in the University of Tokyo Hospital are pre-registered as candidates of this study. No exclusion criteria for the reconstruction methods. Well informed and written convent. Patients with the written informed concent are registered when diagnosed as postoperative pneumonia within 14 days after the operation along with the standard diagnostic criteria.

Exclusion criteria

Exclusion criteria: Other infectious disease including SSI is present. History of hyper reactive events caused by carbapenem. The suspected pathogenic microbes of the pneumonia is; MRSA, MDRP, virus, mycoplasma, regionera, clmamigia, MAC, yeast. MRSA or MDRP is present in any culture specimen during the in hospital course. History of epilepsy or barproic acid use. Renal disease with Ccr lower than 20ml/kg.min or requiring hemodialysis.

Design outcomes

Primary

MeasureTime frame
Days required for the treatment of Biapenem Postoperative hospital stay

Secondary

MeasureTime frame
Clinical and bacteriological efficacy rates at each time point during the use of Biapanem.

Countries

Japan

Contacts

Public ContactKoichi Yagi

The University of Tokyo Hospital Department of Gastrointestinal Surgery

Yagik-tky@umin.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026